FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Mangalam Global Enterprise Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024.
Find important information like Listing Exchange, Terms of payment and Entitlement Ratio for Mangalam Global Enterprise Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024. Mangalam Global Enterprise Rights Issue 2024 is listed on NSE while Solara Active Pharma Sciences Rights Issue 2024 is listed on BSE, NSE.
Mangalam Global Enterprise Limited | Solara Active Pharma Sciences Ltd | |
---|---|---|
Logo | ||
Listing At | NSE | BSE, NSE |
Terms of Payment | The entire amount of the Issue Price of ₹20 per Rights Equity Share shall be payable at the time of Application. |
Issue Price of Rs.375/- per share is payable as Rs.131.25 per share on Application. The remaining amount will be called within 24 months from the date of allotment in the Issue or within such extended period as may be determined by the Board or Rights Issue Committee of the Company at its sole discretion from time to time. |
Entitlement | 1 Rights Equity Share(s) for every 7 fully paid-up Equity Shares held on Record Date | 1 Rights Equity Share(s) for every 3 fully paid-up Equity Shares held on Record Date |
Application Form | Application Form | Application Form |
Letter of Offer | Letter of Offer | Letter of Offer |
Registrar | Link Intime India Private Ltd | Cameo Corporate Services Limited |
Lead Managers | Choice Capital Advisors Pvt Ltd |
The issue size of Mangalam Global Enterprise Rights Issue 2024 rights issue is ₹41.20 Crores, whereas Solara Active Pharma Sciences Rights Issue 2024 rights issue size is ₹449.95 Crores.
Mangalam Global Enterprise Limited | Solara Active Pharma Sciences Ltd | |
---|---|---|
Issue Size | 2,06,00,000 shares | 1,19,98,755 shares |
Issue Size (Amount) | ₹41.20 Crores | ₹449.95 Crores |
Issue Price | ₹20 per share | ₹375 per share |
Face Value | ₹2 per share | ₹10 per share |
Find all the important dates related to the rights issue. The record date of Mangalam Global Enterprise Rights Issue 2024 is May 24, 2024 while record date of Solara Active Pharma Sciences Rights Issue 2024 is May 15, 2024.
Mangalam Global Enterprise Limited | Solara Active Pharma Sciences Ltd | |
---|---|---|
Record Date | May 24, 2024 | May 15, 2024 |
Credit of Rights Entitlements | May 27, 2024 | |
Bid/Offer Opens On | Jun 03, 2024 | May 28, 2024 |
Renunciation of Rights Entitlements | Jun 07, 2024 | Jun 05, 2024 |
Bid/Offer Closes On | Jun 12, 2024 | Jun 11, 2024 |
Deemed Date of Allotment | Jun 14, 2024 | Jun 19, 2024 |
Credit Date | Jun 17, 2024 | Jun 19, 2024 |
Listing Date | Jun 19, 2024 | Jun 20, 2024 |
Comparison of Mangalam Global Enterprise Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024 financial data, including total revenue, PAT, and net worth. The table below also includes a list of all relevant documents like the Application Form and Letter of Offer. Related Parties like Lead Manager and Registrar are also mentioned in this section.
Mangalam Global Enterprise Limited | Solara Active Pharma Sciences Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Mangalam Global Enterprise Limited Financial Information (Restated Consolidated)Mangalam Global Enterprise Limited's revenue increased by 11.47% and profit after tax (PAT) rose by 251.25% between the financial year ending with March 31, 2023 and March 31, 2022.
|
Solara Active Pharma Sciences Ltd Financial Information (Restated Consolidated)Solara Active Pharma Sciences Ltd's revenue increased by 13.82% and profit after tax (PAT) rose by 61.85% between the financial year ending with March 31, 2023 and March 31, 2022.
|
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|